Sun Pharma to CNBC-TV18 -'We approached Daiichi Sankyo first for the Ranbaxy deal' -Proposed merger route to avoid complications of 2 listed entities -SilverStreet Investment in Ranbaxy not connected to deal -SilverStreet's Investment was not precursor to Sun-Ranbaxy deal -Deal with Ranbaxy is fully in compliance with all laws -No ground for insider trading charges against company -Have not heard from SEBI w.r.t. insider trading charges -Have no doubt in keeping Ranbaxy brand alive -Will strengthen Ranbaxy mother brand & sub-brands -Will leverage the strength of Ranbaxy brand in other markets -Foray into Japan will be independent of Daiichi Sankyo -Daiichi's marketing relationship with Ranbaxy to continue -Daiichi's arbitration with Singh brothers not discussed -Synergies of USD 250 million over 3 years not a conservative target -Ranbaxy management to continue till deal formally concludes -Daiichi says consent decree progressing as per schedule -Don't see Ranbaxy deal facing problems in getting Competition Commission of India (CCI) nod -Will assess synergies of manufacturing capacities globally -Confident that Ranbaxy can monetise first-to-file US drug opportunities.